Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the ...

Healthcare Investors lagged its benchmark as biotech faced regulatory hurdles and market rotation. Read the full analysis for ...

According to the note, the broker has retained its speculative buy rating and 25 cents price target on the ASX biotech stock.

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs ...

Some proposed clinical trial rules could create hurdles for smaller countries while failing to ensure high quality and ...

Engineered microorganisms are widely used in industrial biotechnology and biopharmaceutical applications, including the ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsSteven Harr - President, ...

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

Thesis: the pancreatic-cancer trial signal (44% vs 22% one-year survival; longer median survival) is the measurable step that ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...